Your Messages Inbox
Your Article Summary
See Latest ArticlesExon Skipping Therapy Shows Promise in Prevention or Delay of Heart Disease Associated with Duchenne Muscular Dystrophy
AVI BioPharma, 10/20/09
AVI BioPharma, Inc., a developer of RNA–based drugs, announced the publication of research demonstrating the ability of a peptide–conjugated phosphorodiamidate morpholino oligomer therapy to prevent the onset of cardiomyopathy in a mouse model of Duchenne muscular dystrophy. The paper “Long–Term Improvement in mdx Cardiomyopathy after Therapy with Peptide–conjugated Morpholino Oligomers” was authored by researchers at the University of North Carolina at Chapel Hill and AVI and published online, in advance of print, in the journal Cardiovascular Research.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Freeze-Thaw Performance and Robustness Assessment of Celsius FFT 6L
BioPharm, 12/09/09
Bivariate Random Effects Meta-Analysis of Diagnostic Studies Using Generalized Linear Mixed Models
Medical Decision Making, 12/09/09
The Impact of Disposables on Project Economics in a New Antibody Plant
BioPharm, 12/09/09
Article Search
Sponsor